Stock-PR Reporting
FREE Daily Stock Alerts From Stock-PR.com
________________________________________
Power3 Medical Products, Inc. (PWRM.OB) is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS diseases, currently engaged in Phase II clinical trials. These products are designed to analyze proteins and their mutations to assess an individual’s risk for developing disease later in life, a patient’s likelihood of responding to a particular drug, a patient’s risk of disease progression and disease recurrence, to measure a patient’s exposure to drug therapy, to ensure optimal dosing and reduced drug toxicity.
Power3 reported that it has filed two provisional patent applications with the United States Patent and Trademark Office (USPTO) – one on Alzheimer’s disease specific differential diagnosis in the clinical setting and the other on important differences in pathophysiology and therapeutic options for the genetically distinct groups of Alzheimer’s disease patients.
Arrowhead Research Corporation (NASDAQ:ARWR) reported that it has closed its previously announced registered direct offering of 6.6 million shares of common stock and warrants to purchase 3.3 million shares of common stock. Total proceeds from the offering were $8.65 million. The offering strengthens Arrowhead’s balance sheet and enables continued progress with its current subsidiaries while also positioning the company to take advantage of new opportunities.
“Our lead subsidiaries, Calando and Unidym, are making significant progress and the current offering is important to continuing this momentum,” said Christopher Anzalone, Arrowhead’s CEO. “Calando’s first ever demonstration of systemic siRNA delivery and gene silencing in humans was a considerable achievement, and our augmented balance sheet will better enable us to maximize its value by approaching potential partnerships from a position of strength. Similarly, Unidym has made great progress entering touch panel markets, and we are now in a better position to negotiate commercial alliances and strategic investments into that company. In addition, we are looking to ramp up our activity in nanomedicine by adding a new subsidiary to our portfolio and increasing our positions in our existing minority investments.”
The stock and warrants were sold in units, at a price of $1.312 per unit, with each unit consisting of one share of common stock and a warrant to purchase one-half of one share of common stock. Oppenheimer & Co. Inc. was the sole placement agent for the offering. The warrants have an exercise price of $1.65 and are exercisable beginning December 23, 2010.
Arrowhead Research Corporation is a nanotechnology company commercializing new technologies in the areas of life sciences and electronics. Arrowhead is seeking to build value for shareholders through the progress of its portfolio companies. Currently, Arrowhead is focused primarily on its two majority owned subsidiaries, Unidym, a leader in carbon nanotube technology for electronic applications, and Calando, at the forefront of clinical application of RNAi delivery technology. Arrowhead also has minority investments in two privately held nanobiotech companies.
LECG Corporation (NasdaqGS: XPRT) is a global expert services and consulting firm with approximately 1000 professionals in 39 global locations. The firm provides independent expert testimony, financial advisory services, original authoritative studies, strategic advisory, and tax, assurance, and business consulting services to clients including Fortune Global 500 corporations, major law firms, and local, state, and federal governments and agencies in the U.S., Central and South America, Europe, and Asia-Pacific. LECG’s highly credentialed experts and professional staff conduct economic and financial analyses to provide objective opinions and advice regarding complex disputes and inform legislative, judicial, regulatory, and business decision makers. In addition, the firm assists clients in major sectors with compliance and business process improvement consulting.
A report by respected global expert services and consulting firm LECG, reveals that the Neal Bill (HR 3424) will have no impact on Florida homeowner insurance rates or reinsurance capacity. In addition, the report applies the methodology from the Brattle Group Update directly in support of this finding. “Respected Economists Warn that New Insurance Tax Will Have Devastating Effect on Consumers.”
Christian DesRochers, FSA, MAAA senior managing director at LECG stated, “The Neal Bill addresses the treatment of offshore reinsurers headquartered outside the United States that assume reinsurance from affiliated companies in the US Affiliate reinsurance does not remove risk from a group of related companies or add additional capacity to the market. In contrast, unaffiliated (third-party) reinsurance, which is expressly unaffected by the legislation does reallocate risk and add overall capacity.”
Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading shares for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB).
Sign Up For Free Stock Alerts At http://stock-pr.com/signup
________________________________________
Be Sure To Visit stock-pr.ning.com
**********************************************************************
The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings, Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.
